MSTN and cancer: Preclinical studies with anti-MSTN treatments (anti-MSTN antibodies, MSTN propeptide with inhibitory function, inhibitors of the MSTN receptor, activin-receptor IIB) have been conducted, providing encouraging results in the field of skeletal muscular dystrophy, aging and cancer-related cachexia.